A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Clinical trial NCT05199584 · COMPLETED

Trial details

NCT number: NCT05199584
Sponsor: Endeavor Biomedicines, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Solid Tumors With PTCH1 Loss-of-function Mutations

Start date: 2022-05-24
Primary completion: 2024-02-20
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.